Broad-spectrum kinase inhibitor oncolytic

Drugs of the Future

Volumn 36, Issue 1, 2011, Pages 17-23

  Marrari, A ^a   George, S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOMER 17; REGORAFENIB; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; COLORECTAL CANCER; DESQUAMATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL CARCINOMA; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MUCOSA INFLAMMATION; OVARY CANCER; PANCREAS CANCER; RASH; REVIEW; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84952979890     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.01.1568343     Document Type: Review

References (38)

1. Scott, W.J., Joel, R., Ridel, B. et al. (Bayer Healthcare LLC). omega-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors. US 2002042517.
2. Dumas, J., Lynch, M., Scott, W.J., Ladouceur, G., Wilhelm, S. (Bayer Pharmaceuticals Corp.). Diaryl ureas with kinase inhibiting activity. CA 2526617, EP 1636585, JP 200751103, US 2007020704, WO 2004113274.
3. Dumas, J., Wilhelm, S., Boyer, S., Riedl, B. (Bayer Pharmaceuticals Corp). Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions. EP 1663978, JP 2006528196, US 2005038080, WO 2005009961.
4. Dagher, R., Cohen, M., Williams, G. et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002, 8(10): 3034-8. (Pubitemid 35155011)
5. Jänne, P.A., Gray, N., Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009, 8(9): 709-23.
6. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19): 7099-109. (Pubitemid 39331023)
7. Llovet, J.M., Ricci, S., Mazzaferro, V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4): 378-90.
8. Escudier, B., Eisen, T., Stadler, W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2): 125-34. (Pubitemid 46089673)
9. Wilhelm, S.M., Dumas, J., Adnane, L. et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2010, Epub ahead of print.
10. Dhillon, A.S., Hagan, S., Rath, O. et al. MAP kinase signalling pathways in cancer. Oncogene 2007, 26(22): 3279-90. (Pubitemid 46763021)
11. Lipworth, A.D., Robert, C., Zhu, A.X. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology 2009, 77(5): 257-71.
12. Izzedine, H., Ederhy, S., Goldwasser, F. et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009, 20(5): 807-15.
13. Gurevich, F., Perazella, M.A. Renal effects of anti-angiogenesis therapy: Update for the internist. Am J Med 2009, 122(4): 322-8.
14. Izzedine, H., Massard, C., Spano, J.P. et al. VECF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010, 46(2): 439-48.
15. Torino, F., Corsello, S.M., Longo, R. et al. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6(4): 219-28.
16. Bellmunt, J., Eisen, T., Fishman, M., Quinn, D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2010, Epub ahead of print.
17. th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 2558.
18. rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 3593.
19. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 5033.
20. th ECCO and 34th ESMO (Sept 20-24, Berlin) 2009] 2009, 7(2): Abst O-7105.
21. th Eur Soc Med Oncol (ESMO) Congr (Oct 8-12, Milan) 2010] 2010, 21(Suppl. 8): Abst 123P.
22. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 3560.
23. th Eur Soc Med Oncol (ESMO) Congr (Oct 8-12, Milan) 2010] 2010, 21(Suppl. 8): Abst 619P.
24. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 3035.
25. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 7585.
26. Determination of safety, efficacy, and pharmacokinetics of "regorafenib" combined with pemetrexed and cisplatin in patients with nonsquamous non-small cell lung cancer (NCT01187615). ClinicalTrials.gov Web site, January 3, 2011.
27. Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy (NCT01103323). ClinicalTrials.gov Web site, January 3, 2011.
28. Study to determine safety, pharmacokinetics, pharmacodynamics of BAY73-4506 in combination with mFOLFOX6 or FOLFIRI (NCT00934882). ClinicalTrials.gov Web site, January 3, 2011.
29. Safety study of BAY73-4506 in patients with hepatocellular carcinoma (NCT01003015). ClinicalTrials.gov Web site, January 3, 2011.
30. Ainsworth, N.L., Lee, J.S., Eisen, T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009, 9(12): 1793-805.
31. Heinrich, M.C., Corless, C.L., Demetri, G.D. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21(23): 4342-9. (Pubitemid 46621810)
32. Liegl, B., Kepten, I., Le, C. et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008, 216(1): 64-74.
33. Heinrich, M.C., Corless, C.L., Blanke, C.D. et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24(29): 4764-74. (Pubitemid 46630941)
34. Engelman, J.A., Zejnullahu, K., Mitsudomi, T. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827): 1039-43. (Pubitemid 46799492)
35. Demetri, G.D., van Oosterom, A.T., Garrett, C.R. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006, 368(9544): 1329-38. (Pubitemid 44528723)
36. th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 10502.
37. Regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (NCT01068769). ClinicalTrials.gov Web site, January 3, 2011.
38. Study of regorafenib as a 3rd-line or greater treatment for gastrointestinal stromal tumors (GIST) (NCT01271712). ClinicalTrials.gov Web site, January 3, 2011.